logo
Plus   Neg
Share
Email

Proteostasis Therapeutics (PTI) Is Climbing On FDA Breakthrough Designation

Proteostasis Therapeutics Inc. (PTI) announced after the bell Monday that it has been granted Breakthrough Therapy Designation from the FDA for its cystic fibrosis transmembrane conductance regulator amplifier, PTI-428. The stock is now up 1.39 on 574K shares.

Proteostasis Therapeutics traded in a range for the majority of Monday's session and closed up by 0.02 at $4.14.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT